Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial ...
94.5% of R&D expenses related to obefazimod in the first quarter of 2026 compared to 98.5% in the first quarter of 2025.
Republicans in Congress are raising renewed concerns about collaborations between scientists in the US and China, a push ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results